The overall goal of the diAB-RDCC is to stimulate collaborative and innovative interdisciplinary research in order to enhance our fundamental understanding of disease mechanisms and their application to human rheumatic diseases. Through this understanding, the UAB-RDCC's goal is to improve the diagnosis and treatment of patients with arthritis and musculoskeletal diseases. The strategy of the UAB-RDCC is to draw on the strengths of the UAB research community, including the Hudson Alpha Institute of Biotechnology and Southern Research, to provide essential scientific tools and technologies, to enlist new investigators, to foster the sharing of knowledge and to nuture collaborations among translational and basic science investigators in the fight against rheumatic diseases through the creation and support of a vibrant scientific culture of discovery and innovation. Accordingly, our specific aims are 1) to facilitate rheumatic disease research through Research Core facilities, which provide scientifically rigorous, state-of-the-art techniques necessary for improved understanding of disease pathogenesis and the development of new treatments;2) to support outstanding Pilot &Feasibility research projects drawing on the unique strengths of the RDCC research base and using innovative tools and approaches in biomedical science;and 3) to provide career development and career enrichment activities to enhance both the mentorship of talented investigators as independent researchers and the continuing education of all of our investigators. To achieve its specific aims, the UAB-RDCC has worked continuously with its Research Core facilities to develop technical capacities, to assess user needs and to provide a variety of formats for outreach and enrichment, including our IDEAs program (individualized design and experimental analyses sessions). The RDCC leadership team has worked with the School of Medicine, the Provost, the Vice President for Research and the Faculty Practice (HSF-GEF) to support the continued development of available tools and technologies for rheumatic diseases research, and through these efforts the UAB-RDCC provides the opportunity for our investigators to commit their programs to the mission of NIAMS.

Public Health Relevance

The UAB-RDCC is committed to providing both the critical tools and technologies and the vibrant scientific environment to enhance discovery and innovation in rheumatic diseases research in order to improve the diagnosis and treatment of patients with arthritis and musculoskeletal diseases. To achieve these goals, the UAB-RDCC provides core facilities and supports both pilot research programs and a vigorous outreach and enrichment program of seminars, symposia, workshops and individualized IDEA sessions.

Agency
National Institute of Health (NIH)
Institute
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Type
Center Core Grants (P30)
Project #
5P30AR048311-13
Application #
8725927
Study Section
Special Emphasis Panel (ZAR1-KM (M1))
Program Officer
Mao, Su-Yau
Project Start
2001-09-28
Project End
2017-08-31
Budget Start
2014-09-01
Budget End
2015-08-31
Support Year
13
Fiscal Year
2014
Total Cost
$586,550
Indirect Cost
$181,350
Name
University of Alabama Birmingham
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
063690705
City
Birmingham
State
AL
Country
United States
Zip Code
35294
Ladowski, Joseph M; Martens, Gregory R; Reyes, Luz M et al. (2018) Examining the Biosynthesis and Xenoantigenicity of Class II Swine Leukocyte Antigen Proteins. J Immunol 200:2957-2964
Hough, Kenneth P; Wilson, Landon S; Trevor, Jennifer L et al. (2018) Unique Lipid Signatures of Extracellular Vesicles from the Airways of Asthmatics. Sci Rep 8:10340
Chou, Chu-Fang; Hsieh, Yu-Hua; Grubbs, Clinton J et al. (2018) The retinoid X receptor agonist, 9-cis UAB30, inhibits cutaneous T-cell lymphoma proliferation through the SKP2-p27kip1 axis. J Dermatol Sci 90:343-356
Friedman, Gregory K; Bernstock, Joshua D; Chen, Dongquan et al. (2018) Enhanced Sensitivity of Patient-Derived Pediatric High-Grade Brain Tumor Xenografts to Oncolytic HSV-1 Virotherapy Correlates with Nectin-1 Expression. Sci Rep 8:13930
Garner, Evan F; Williams, Adele P; Stafman, Laura L et al. (2018) FTY720 Decreases Tumorigenesis in Group 3 Medulloblastoma Patient-Derived Xenografts. Sci Rep 8:6913
Ladowski, Joseph M; Reyes, Luz M; Martens, Gregory R et al. (2018) Swine Leukocyte Antigen Class II Is a Xenoantigen. Transplantation 102:249-254
Harms, Ashley S; Thome, Aaron D; Yan, Zhaoqi et al. (2018) Peripheral monocyte entry is required for alpha-Synuclein induced inflammation and Neurodegeneration in a model of Parkinson disease. Exp Neurol 300:179-187
Lever, Jeremie M; Yang, Zhengqin; Boddu, Ravindra et al. (2018) Parabiosis reveals leukocyte dynamics in the kidney. Lab Invest 98:391-402
Chakraborty, Asmi; Dorsett, Kaitlyn A; Trummell, Hoa Q et al. (2018) ST6Gal-I sialyltransferase promotes chemoresistance in pancreatic ductal adenocarcinoma by abrogating gemcitabine-mediated DNA damage. J Biol Chem 293:984-994
Su, Hairui; Sun, Chiao-Wang; Liu, Szu-Mam et al. (2018) Defining the epigenetic status of blood cells using a cyanine-based fluorescent probe for PRMT1. Blood Adv 2:2829-2836

Showing the most recent 10 out of 340 publications